Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Island Pharmaceuticals Ltd ( (AU:ILA) ) has shared an announcement.
Island Pharmaceuticals Ltd presented new data from its Phase 2a/b PROTECT trial at the Third Annual Dengue Endgame Summit, showcasing the effectiveness of its antiviral drug ISLA-101 in reducing viral load and improving infection markers in dengue patients. This presentation, attended by global dengue experts, highlights the potential of ISLA-101 as a dengue countermeasure and supports the company’s ongoing development efforts, potentially enhancing its industry positioning and stakeholder engagement.
More about Island Pharmaceuticals Ltd
Island Pharmaceuticals Ltd is an Australian antiviral drug development company focused on addressing urgent viral diseases, public health, or biosecurity threats. The company is executing a dual development strategy for its assets, ISLA-101 and Galidesivir. ISLA-101 is being repurposed for the prevention and treatment of dengue fever and other mosquito-borne diseases, while Galidesivir is a clinical-stage antiviral molecule with broad-spectrum activity against over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika, and Yellow fever.
Average Trading Volume: 725,794
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$51.71M
For detailed information about ILA stock, go to TipRanks’ Stock Analysis page.